Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.
Oncolytics Biotech Price Performance
The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The company has a 50 day moving average of C$14.90 and a 200 day moving average of C$14.90.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
